Alito Temporarily Restores FDA Rule on Abortion Pill

On May 4, 2026, U.S. Supreme Court Justice Samuel Alito issued a temporary stay reinstating the Food and Drug Administration's (FDA) rule that permits the abortion pill mifepristone to be prescribed online and distributed via mail. This decision comes in response to an appellate court order that had previously blocked the FDA's regulation, effectively restricting access to mifepristone.

The temporary relief granted by Justice Alito benefits Danco Laboratories, the manufacturer of mifepristone, and GenBioPro, the producer of its generic version. The administrative stay is set to remain in effect until 5 p.m. on May 11, providing the Supreme Court additional time to deliberate on the pharmaceutical companies' requests to overturn the appellate court's ruling while ongoing litigation continues.

Mifepristone, commonly used in medication abortions, has been a focal point in the broader national discourse on reproductive rights. The FDA's rule allowing its prescription through telemedicine and mail delivery was seen as a significant step in expanding access to abortion services, especially in areas with limited healthcare facilities. The appellate court's decision to block this rule had raised concerns among reproductive rights advocates about potential barriers to access.

Legal experts suggest that the Supreme Court's forthcoming decision could have profound implications for the FDA's authority in regulating medication distribution and the broader landscape of reproductive healthcare in the United States. Stakeholders on both sides of the debate are closely monitoring the situation, anticipating further developments as the May 11 deadline approaches.

For more detailed information, refer to the original article on CBS News: Alito temporarily restores FDA rule allowing abortion pill mifepristone to be sent by mail.